全文获取类型
收费全文 | 657篇 |
免费 | 29篇 |
专业分类
耳鼻咽喉 | 11篇 |
儿科学 | 40篇 |
妇产科学 | 9篇 |
基础医学 | 55篇 |
口腔科学 | 21篇 |
临床医学 | 37篇 |
内科学 | 88篇 |
皮肤病学 | 45篇 |
神经病学 | 47篇 |
特种医学 | 22篇 |
外科学 | 188篇 |
综合类 | 8篇 |
预防医学 | 20篇 |
眼科学 | 11篇 |
药学 | 39篇 |
中国医学 | 1篇 |
肿瘤学 | 44篇 |
出版年
2023年 | 5篇 |
2022年 | 13篇 |
2021年 | 19篇 |
2020年 | 19篇 |
2019年 | 20篇 |
2018年 | 21篇 |
2017年 | 22篇 |
2016年 | 9篇 |
2015年 | 14篇 |
2014年 | 30篇 |
2013年 | 42篇 |
2012年 | 61篇 |
2011年 | 60篇 |
2010年 | 42篇 |
2009年 | 23篇 |
2008年 | 24篇 |
2007年 | 26篇 |
2006年 | 39篇 |
2005年 | 37篇 |
2004年 | 36篇 |
2003年 | 39篇 |
2002年 | 38篇 |
2001年 | 10篇 |
2000年 | 2篇 |
1999年 | 5篇 |
1998年 | 1篇 |
1997年 | 2篇 |
1995年 | 1篇 |
1994年 | 3篇 |
1993年 | 2篇 |
1991年 | 1篇 |
1990年 | 2篇 |
1989年 | 1篇 |
1988年 | 4篇 |
1987年 | 1篇 |
1986年 | 1篇 |
1985年 | 3篇 |
1983年 | 1篇 |
1982年 | 1篇 |
1981年 | 1篇 |
1979年 | 2篇 |
1978年 | 2篇 |
1974年 | 1篇 |
排序方式: 共有686条查询结果,搜索用时 0 毫秒
111.
Navaratnam S Skliris G Qing G Banerji S Badiani K Tu D Bradbury PA Leighl NB Shepherd FA Nowatzki J Demers A Murphy L 《Hormones & cancer》2012,3(3):93-100
Although women have an increased susceptibility to lung cancer, they also have a favorable clinical outcome. This may in part be due to female specific genetic and hormonal factors. In the present study, expression of ER-beta was investigated by immunohistochemistry using tissue samples from two cohorts: non-small cell lung cancer (NSCLC) diagnosed in 1999 in Manitoba and advanced NSCLC patients from the NCIC-CTG BR.18 trial. In the Manitoba cohort assessable tissue samples available in 79 patients (32 females and 47 males) and the majority (75%) had early stage disease. Fifty-one percent of patients expressed high levels of ER-beta (defined by ≥60, the median immunohistochemistry score) and its expression was comparable in males and females. The 3-year overall survival of the group was 53% and males had significantly worse survival compared to females (HR=2.37, 95%CI 1.15–4.91, P=0.02). Higher ER-beta 1 expression was associated with better survival in both univariate (HR=0.41, 95%CI 0.21–0.80, P=0.009) and in multivariate (HR=0.37, 95%CI 0.18–0.77, P=0.008) analysis. In the NCIC-CTG cohort that were more often later stage, assessable tissue samples from 48 cases were available however higher ER beta 1 expression correlated with poorer survival (HR= 1.94, 95%CI 1.01–3.75 P=0.047). These results suggest a differential impact of ER-beta 1 expression on clinical outcome by disease stage, that needs to be explored further and may explain contradictory observations reported in the literature. 相似文献
112.
113.
Brown VA Patel KR Viskaduraki M Crowell JA Perloff M Booth TD Vasilinin G Sen A Schinas AM Piccirilli G Brown K Steward WP Gescher AJ Brenner DE 《Cancer research》2010,70(22):9003-9011
Resveratrol, a naturally occurring polyphenol, has cancer chemopreventive properties in preclinical models. It has been shown to downregulate the levels of insulin-like growth factor-1 (IGF-I) in rodents. The purpose of the study was to assess its safety, pharmacokinetics, and effects on circulating levels of IGF-I and IGF-binding protein-3 (IGFBP-3) after repeated dosing. Forty healthy volunteers ingested resveratrol at 0.5, 1.0, 2.5, or 5.0 g daily for 29 days. Levels of resveratrol and its metabolites were measured by high performance liquid chromatography-UV in plasma obtained before and up to 24 hours after a dose between days 21 and 28. IGF-I and IGFBP-3 were measured by ELISA in plasma taken predosing and on day 29. Resveratrol was safe, but the 2.5 and 5 g doses caused mild to moderate gastrointestinal symptoms. Resveratrol-3-O-sulfate, resveratrol-4'-O-glucuronide, and resveratrol-3-O-glucuronide were major plasma metabolites. Maximal plasma levels and areas under the concentration versus time curve for the metabolites dramatically exceeded those for resveratrol, in the case of areas under the concentration versus time curve, by up to 20.3-fold. Compared with predosing values, the ingestion of resveratrol caused a decrease in circulating IGF-I and IGFBP-3 (P<0.04 for both), respectively, in all volunteers. The decrease was most marked at the 2.5 g dose level. The results suggest that repeated administration of high doses of resveratrol generates micromolar concentrations of parent and much higher levels of glucuronide and sulfate conjugates in the plasma. The observed decrease in circulating IGF-I and IGFBP-3 might contribute to cancer chemopreventive activity. 相似文献
114.
Ketan R Bulsara Asiri Ediriwickrema Joshua Pepper Fergus Robertson John Aruny Joseph Schindler 《World Journal of Clinical Cases》2013,1(9):290-294
Tandem internal carotid and middle cerebral artery occlusion after carotid dissection predicts poor outcome after systemic thrombolysis. Current treatments include the use of endovascular carotid stenting, which carries with it a high risk of propagating further embolic events and worsening the dissection. New strategies for avoiding the aforementioned side-effects include recanalization using cross-collaterals for delivery of intra-lesional tissue plasminogen activator (tPA). We present two cases that provide further support for this novel approach. Both patients presented with a National Institute of Health Stroke Scale of 20, received intra-arterial tPA via cross-collateralization, and made full recoveries without the need for stenting. 相似文献
115.
116.
117.
S. V. Deshpande S. S. Bhatwadekar Parth Desai Tarang Bhavsar Ankit Patel Amey Koranne Arpan Mehta Shweta Khadse 《Indian journal of hematology & blood transfusion》2016,32(2):215-220
Sickle cell disease (SCD) is common in tribal belt of Gujarat, but not addressed effectively as it should be with effective use of Hydroxyurea, supportive care and counseling. In our single centre study of 70 patients of SCD who were only on Folic acid and Blood transfusion support, were analyzed and followed up for 1 year in terms of their clinical symptoms, Blood transfusion requirement, laboratory parameters before and after Hydroxyurea therapy. We found statistically significant improvement in clinical symptoms and positive changes in laboratory parameters studied. This validates the well established role of Hydroxyurea in SCD as seen in the various international trials. Hence it is imperative that the well documented benefits of Hydroxyurea in various International studies should be translated into clinical practice. SCD should be treated like a chronic disorder needing preventive therapy in form of Hydroxyurea and counseling with regular follow up. 相似文献
118.
Ketan Badani Darby J. S. Thompson Christine Buerki Elai Davicioni Jill Garrison Mercedeh Ghadessi Anirban P. Mitra Penelope J. Wood John Hornberger 《Oncotarget》2013,4(4):600-609
Background
Only a minority of prostate cancer patients with adverse pathology and biochemical recurrence (BCR) post radical prostatectomy (RP) experience metastasis and die from prostate cancer. Improved risk prediction models using genomic information may enable clinicians to better weigh the risk of metastasis and the morbidity and costs of treatment in a clinically heterogeneous population.Purpose
We present a clinical utility study that evaluates the influence on urologist treatment recommendations for patients at risk of metastasis using a genomic-based prediction model (DecipherTM).Methods
A prospective, pre-post design was used to assess urologist treatment recommendations following RP in both the adjuvant (without any evidence of PSA rise) and salvage (BCR) settings. Urologists were presented de-identified pathology reports and genomic classifier (GC) test results for 24 patients from a previously conducted GC validation study in high-risk post-RP men. Participants were fellowship trained, high-volume urologic oncologists (n=21) from 18 US institutions. Treatment recommendations for secondary therapy were made based solely on clinical information (pre-GC) and then with genomic biomarker information (post-GC). This study was approved by an independent IRB.Results
Treatment recommendations changed from pre-GC to post-GC in 43% of adjuvant, and in 53% of salvage setting case evaluations. In the adjuvant setting, urologists changed their treatment recommendations from treatment (i.e. radiation and/or hormones) to close observation post-GC in 27% of cases. For cases with low GC risk (<3% risk of metastasis), observation was recommended for 79% of the case evaluations post-GC. Consistent trends were observed in the salvage setting.Conclusion
These results indicate that urologists across a range of practice settings are likely to change treatment decisions when presented with genomic biomarker information following RP. Implementation of genomic risk stratification into routine clinical practice may better direct treatment decision-making post-RP. 相似文献119.
120.
Genital Warts 总被引:4,自引:0,他引:4